The primary reason is that CD47 lacks cancer specificity and is widely distributed in healthy tissues, leading to a substantial “antigen sink”; thus, high doses of anti-CD47 drugs are required to attain anticancer efficacy. This evidence concerns the gene CD47 and cancer.